Brazil’s ANVISA clears Fiocruz for HIV combo production



Brazil’s Institute of Technology and Pharmaceuticals (Farmanguinhos) of the Oswaldo Cruz Foundation (Fiocruz) has been approved by the National Health Surveillance Agency (ANVISA) to produce tenofovir disoproxil + lamivudine, a generic version of local laboratory Blanver’s Duplivir. Fiocruz had announced the completed production of pilot batches of the antiretroviral earlier this month, as GBI reported.

The milestone is the result of a technology transfer deal signed in 2014 under a Productive Development Partnership (PDP), and involves the local production of the active pharmaceutical ingredients (APIs). Farmanguinhos plans to supply the Unified Health System (SUS) with 75 million tablets by year end, and over 140 million by 2020.

Reference:

Related news
China-based Fujian Cosunter Pharmaceutical Co., Ltd, (300436.SZ) is readying to file an Investigational New Drug (IND) application with the National Medical Products Administration (NMPA) in relation to novel liver cancer drug candidate GST-HG141.
The World Health Organization (WHO) has issued a report on HIV drug resistance in 24 countries, including 8 in Latin America.
  • 1565763122551
  • Brazil,Mexico,Colombia,Cuba,Guatemala,Argentina,Nicaragua,Honduras
  • Policy/Regulatory
Chile’s Institute of Public Health (ISP) last week published the approval it granted to Argentina-based laboratory Gador’s Gilead-licensed anti-HIV drug Biktarvy (bictegravir + emtricitabine + tenofovir alafenamide), according to GBI analysis.
US-based Gilead Sciences Inc., announced market approval from the National Medical Products Administration (NMPA) for its bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF; trade name: Biktarvy), a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection.
Chile’s Ministry of Health (MoH) last week initiated the free distribution of Gilead’s HIV pre-exposure prophylaxis (PrEP) drug Truvada (emtricitabine + tenofovir).
Recent news
Taiwan-based firm TaiGen Biophamaceuticals Holdings Ltd picked up a milestone payment of USD 5 million from Yichang HEC Changjiang Pharmaceutical Co., Ltd, its co-development partner for the hepatitis C virus (HCV) therapy furaprevir in China.
Innovative Chinese biotech Nanjing Frontier Biotech announced that it plans to raise RMB 2.01 billion (USD 286 million) through an initial public offering (IPO) to the Science and Technology Innovation Board (STAR) hosted by the Shanghai Stock Exchange (SSE).
  • 1566271018353
  • China
WuXi Biologics (Cayman) Inc. (HKEX.2269) released financial results for the H1’19 period ended June 30, 2019.
Pharmaceutical major Amgen has transferred Dominican Republic-born Elvin Penn from its Mexico subsidiary to head its operations in Brazil.
A team of researchers in Argentina has identified tumor-supportive mechanisms derived from interactions between fibroblasts and anaplastic thyroid cancer cells, the most aggressive type of thyroid cancer with a worse prognosis for patients.
  • 1566206139500
  • Argentina
  • R&D
Shanghai-based Haihe Biopharma announced its latest in-licensing and partnership deal with the Shanghai Institute of Materia Medica (SIMM, affiliated to the Chinese Academy of Sciences) and Jinan University.
  • 1566205390010
  • China
  • Drug
GBI analysis reveals that Chile’s Institute of Public Health (ISP) last week published its approval of Austria-based Ever Pharma Jena’s Everpressin (terlipressin), a first-mover generic version of Switzerland-based Ferring’s hormone analogue Glypressin.
Analytics Snapshot